Through the proposal, BARDA seeks to procure 1.7 million courses of a smallpox antiviral.
The proposal states that the contract would contain an option to obtain up to 12 million additional courses.
Responses to the new proposal are due on 28 February 2011, after BARDA’s previous Request for Proposal on this subject, number 09-35, were cancelled.
SIGA chairman and CEO Eric Rose said the new Request for Proposal confirms the government’s commitment to a robust biodefense and the procurement of meaningful, new medical countermeasures against serious biothreats.
"SIGA intends to respond to this Request for Proposal, and we believe that we are well positioned to meet the government’s needs," Rose said.